Results 21 to 30 of about 36,254 (205)

Anticoagulant effects of rivaroxaban, prednisone, alone and in combination, in healthy dogs

Journal of Veterinary Internal Medicine, 2022
Background The potential effects of glucocorticoid administration on rivaroxaban's anticoagulant bioactivity in dogs, and an appropriate rivaroxaban dosage regimen for dogs receiving glucocorticoid therapy are unknown. Hypothesis/Objectives The objective
Paige M. Hafner, Andrew J. Mackin, Robert W. Wills, Marjory B. Brooks, John M. Thomason   +4 more
doaj   +1 more source

The effects of rivaroxaban, an oral anticoagulant, on human IVD primary cultures [PDF]

, 2021
Introduction: The present study aimed to investigate the potential effects of rivaroxaban, an oral anticoagulant that inhibits the effects of factor Xa, on intact intervertebral disc tissue cells and the extracellular matrix (ECM).
Yılmaz, İbrahim, Sirin, Duygu Yasar, Caliskan, Tezcan, Çalışkan, Tezcan, Yilmaz, Ibrahim, Özbek, Hanefi, Akalan, Hande, Karaarslan, Numan, Yaşar Şirin, Duygu, Tezcan Caliskan, Numan Karaarslan, Duygu Yasar Sirin, Hande Akalan, Hanefi Ozbek, Ibrahim Yilmaz   +14 more
core   +1 more source

Real-world experience in managing atrial fibrillation in patients with renal impairment; Rivaroxaban versus warfarin

Heart Views, 2023
Background: The use of rivaroxaban in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) poses the risk of over- or underdosing. We aimed to compare rivaroxaban and warfarin in AF patients with moderate and severe renal impairment ...
Monirah Abdulrahman Albabtain, Zaid Dakheel Alanazi, Nawaf Hamoud Al-Mutairi, Ola Alyafi, Raneem Albanyan, Amr A Arafat   +5 more
doaj   +1 more source

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation [PDF]

, 2014
A John Camm,1 Pierre Amarenco,2 Sylvia Haas,3 Susanne Hess,4 Paulus Kirchhof,5,6 Martin van Eickels,4 Alexander GG Turpie71Division of Clinical Sciences, St George's, University of London, London, UK; 2Department of Neurology and Stroke Center, Paris-
Hess, S, Camm, AJ, Amarenco, Pierre, Eickels MV, Turpie, AG, Hess, Susanne, Haas, S, Turpie, Alexander G G, Kirchhof, P, van Eickels, M, Haas, Sylvia, Kirchhof, Paulus; id_orcid, Amarenco, P, Camm AJ, Hess S, Camm, John, Amarenco P, Van Eickels, Martin, Turpie AGG, Kirchhof P, Haas S   +20 more
core   +1 more source

The Study of Cost-Effectiveness of Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Who Developed Ischemic Stroke

Stroke Research and Treatment, 2021
Introduction. Rivaroxaban is a new anticoagulant providing benefits for the treatment of patients with atrial fibrillation (AF). This study is aimed at evaluating the cost-effectiveness of rivaroxaban compared to warfarin in patients with AF.
Neda Jaberi, Zahra Kavosi, Etrat Hooshmandi, Nasrin Moradi, Khosro Keshavarz, Afshin Borhani-Haghighi   +5 more
doaj   +1 more source

Rivaroxaban Induced Hallucinations: A Case Report [PDF]

, 2022
Hallucinations induced by rivaroxaban are not much described in literature. This case report describes the occurrence of a specific adverse event during rivaroxaban use in an elderly male who developed hallucinations few months after starting rivaroxaban.
Matthew Ferguson, Anshika Balwan, null Anshika Balwan, null Matthew Ferguson   +3 more
core   +1 more source

Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study

BMC Pharmacology and Toxicology, 2020
Background Rivaroxaban, a novel oral anticoagulant drug, is widely used in clinical practice. There is no standardized laboratory monitoring for rivaroxaban, and its plasma concentration in Chinese patients with deep vein thrombosis is unclear.
Ying Li, Liping Du, Xiaowan Tang, Yuexin Chen, Dan Mei   +4 more
doaj   +1 more source

Rivaroxaban prescribing in a Saudi tertiary care teaching hospital

Saudi Pharmaceutical Journal, 2018
Purpose: This drug utilization review (DUR) aimed to describe the use of rivaroxaban in a tertiary care teaching hospital and to audit the hospital physicians’ prescribing practice.
Ahmed Yacoob Mayet, Ahmed Ibrahim Alsaqer, Abdullah Musa Alhammad, Hussain Abdulrahman Al-Omar   +3 more
doaj   +1 more source

Single and Repeated Doses of EGb 761® do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects

Frontiers in Pharmacology, 2022
The present drug-drug interaction study investigates whether single or repeated doses of 240 mg Ginkgo biloba extract EGb 761® alter the pharmacokinetics or pharmacodynamics of rivaroxaban in healthy subjects.
Robert Hoerr, Andrea Zimmermann, Friedeborg Seitz, Angelika Dienel   +3 more
doaj   +1 more source

Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin

Gastroenterology Research and Practice, 2016
Introduction. The risk of gastrointestinal (GI) bleeding with rivaroxaban has not been studied extensively. The aim of our study was to assess this risk in comparison to warfarin. Methods.
Muhammed Sherid, Samian Sulaiman, Salih Samo, Husein Husein, Ruth Tupper, Charles Spurr, Humberto Sifuentes, Subbaramiah Sridhar   +7 more
doaj   +1 more source